Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study
- 12 December 2012
- journal article
- clinical trial
- Published by Wiley in Addiction Biology
- Vol. 18 (6) , 937-946
Abstract
The results of placebo‐controlled trials (RCTs) with acamprosate or naltrexone vary substantially. Those differences have been attributed to differing patient characteristics, recruitment strategies, treatment settings and remuneration systems. We tested these assumptions by comparing a new double–blind, placebo‐controlled randomized trial conducted in Germany (called PREDICT Study) with data from the US COMBINE Study. PREDICT was designed according to the protocol of the COMBINE Study. A total of 426 alcohol‐dependent patients were compared to 459 COMBINE Study patients corresponding to the treatment cells in PREDICT. All patients received acamprosate, naltrexone or placebo for 3 months (PREDICT) or 4 months (COMBINE). Biweekly manualized ‘medical management’ to enhance compliance was delivered in both studies. Time until the first occurrence of heavy drinking was the main outcome measure. PREDICT found neither acamprosate nor naltrexone to supply any additional benefit compared with placebo, which is at variance with a positive naltrexone effect being reported in the COMBINE Study. A secondary comparison between both studies showed better overall treatment outcomes in PREDICT, although these patients had been more severely affected than their COMBINE counterparts. The divergence in results may be attributable to basic differences in the treatment environments (such as in‐patient pre‐treatment versus primary outpatient care). We suggest that identically designed RCTs conducted in different parts of the world may help improve the external validity of RCTs. This approach could be called ‘comparative efficacy research’.Keywords
This publication has 23 references indexed in Scilit:
- Medications development to treat alcohol dependence: a vision for the next decadeAddiction Biology, 2012
- Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatmentAlcohol, 2012
- Pharmacogenetic approaches to the treatment of alcohol addictionNature Reviews Neuroscience, 2011
- Searching for Responders to Acamprosate and Naltrexone in Alcoholism Treatment: Rationale and Design of thePredict StudyAlcohol, Clinical and Experimental Research, 2009
- Acamprosate: Recent Findings and Future Research DirectionsAlcohol, Clinical and Experimental Research, 2008
- Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (The COMBINE Study): Examination of Posttreatment Drinking OutcomesJournal of Studies on Alcohol and Drugs, 2008
- Combined Pharmacotherapies and Behavioral Interventions for Alcohol DependenceJAMA, 2006
- Treatment of Alcohol Abuse: An Evidence‐Based ReviewAlcohol, Clinical and Experimental Research, 2003
- Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of AlcoholismArchives of General Psychiatry, 2003
- Naltrexone in the Treatment of Alcohol DependenceNew England Journal of Medicine, 2001